Vystar Corporation is growing faster than the speed of ultraviolet light
VYST Jun 22, 2020
COVID-19 Healthcare Opinion
VYSTAR CORPORATION
VYST USD 0.0300 -0.0191 / -38.9002%
Volume 167,230,145 | Market Cap 33,620,396 | Shares 1,120,679,936 | PEG Ratio 0.0000 | EPS -0.0090
Vystar Corp. (OTC: VYST) is on a strong rise and this has not escaped the attention of multiple investors. The company has outperformed its own peaks and is emerging as a traded share in small caps. The reason behind the rise is mainly the Rx3000 ultraviolet (UV) air purification system. They focus on the medical world where killing bacteria, viruses and other pathogens in the air is a high priority. In addition, Vystar recently acquired the assets of Fluid Energy Conversion (FEC). FEC has established a position as a global green energy company with a multitude of new technologies, including a range of patented technologies designed to revolutionize energy production and consumption for many consumers.
Exclusive CEO Interview – Thermal Pass Fever Detection Device Detecting Covid In Crowd
The mission of Vystar Corp.
Vystar Corp. (OTC: VYST) has a mission to provide environmentally friendly solutions to complex environmental challenges. They are the exclusive creator and owner of Vytex Natural Rubber Latex (NRL). This is characterized by 100% renewable resources, environmentally friendly processes and fully biodegradable products. Natural Rubber Latex has multiple patents and is now used by many manufacturers. From adhesives and condoms for consumers to mattresses and gloves in hospitals.
Why RxAir is currently in the spotlight
The RxAir UV light air purification products can now be added as a latest development. It’s even said to be the best air purification system in the world. The RxAir products have been certified by the FDA as Class II medical devices and have HEPA filtration of hospital quality. The innovative and patented ViraTech air purification technology uses ultraviolet-C (UV-C) germicidal irradiation (UVGI) to inactivate 99.97% of airborne viruses, bacteria and other pathogens in the first pass. Independently tested by EPA and FDA certified laboratories, it has also been proven to reduce odour and VOC concentrations. The high intensity of the UV lamps destroys the bacteria and viruses instead of locking them up, which is currently the case with the competitors.
Growing means expanding
As a final development, Vystar acquired the assets of Fluid Energy Conversion (FEC). FEC is a recognized global green energy company with a multitude of new technologies. For over 50 years, FEC’s lead scientist has developed and patented successful inventions – nationally and internationally – in fluid mechanics, fluid science, thermodynamics and related physics. The aim is to make these products easy to use, easy to understand and cost-effective to manufacture.
Why is Vystar gaining a lot of interest?
At the time of writing (June 22, 2020), Vystar Corp. has a value increase of +104.37% and the counter continues to rise. Closed at 0.0322 and opened at 0.039, the share currently stands at 0.0711. Especially the fact that this share turns out to surpass itself on a weekly basis tastes like more. It’s going exponentially fast and the apex doesn’t seem to be reached yet. The feeling of not wanting to miss the boat seems to be playing up with several investors. Because of the COVID-19, the medical market is showing a lot of interest. The RxAir is a clever response to this by improving the air quality to such an extent that hospitals want to equip themselves with the Vytex and RxAir products.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.
VYST Jun 22, 2020
COVID-19 Healthcare Opinion
VYSTAR CORPORATION
VYST USD 0.0300 -0.0191 / -38.9002%
Volume 167,230,145 | Market Cap 33,620,396 | Shares 1,120,679,936 | PEG Ratio 0.0000 | EPS -0.0090
Vystar Corp. (OTC: VYST) is on a strong rise and this has not escaped the attention of multiple investors. The company has outperformed its own peaks and is emerging as a traded share in small caps. The reason behind the rise is mainly the Rx3000 ultraviolet (UV) air purification system. They focus on the medical world where killing bacteria, viruses and other pathogens in the air is a high priority. In addition, Vystar recently acquired the assets of Fluid Energy Conversion (FEC). FEC has established a position as a global green energy company with a multitude of new technologies, including a range of patented technologies designed to revolutionize energy production and consumption for many consumers.
Exclusive CEO Interview – Thermal Pass Fever Detection Device Detecting Covid In Crowd
The mission of Vystar Corp.
Vystar Corp. (OTC: VYST) has a mission to provide environmentally friendly solutions to complex environmental challenges. They are the exclusive creator and owner of Vytex Natural Rubber Latex (NRL). This is characterized by 100% renewable resources, environmentally friendly processes and fully biodegradable products. Natural Rubber Latex has multiple patents and is now used by many manufacturers. From adhesives and condoms for consumers to mattresses and gloves in hospitals.
Why RxAir is currently in the spotlight
The RxAir UV light air purification products can now be added as a latest development. It’s even said to be the best air purification system in the world. The RxAir products have been certified by the FDA as Class II medical devices and have HEPA filtration of hospital quality. The innovative and patented ViraTech air purification technology uses ultraviolet-C (UV-C) germicidal irradiation (UVGI) to inactivate 99.97% of airborne viruses, bacteria and other pathogens in the first pass. Independently tested by EPA and FDA certified laboratories, it has also been proven to reduce odour and VOC concentrations. The high intensity of the UV lamps destroys the bacteria and viruses instead of locking them up, which is currently the case with the competitors.
Growing means expanding
As a final development, Vystar acquired the assets of Fluid Energy Conversion (FEC). FEC is a recognized global green energy company with a multitude of new technologies. For over 50 years, FEC’s lead scientist has developed and patented successful inventions – nationally and internationally – in fluid mechanics, fluid science, thermodynamics and related physics. The aim is to make these products easy to use, easy to understand and cost-effective to manufacture.
Why is Vystar gaining a lot of interest?
At the time of writing (June 22, 2020), Vystar Corp. has a value increase of +104.37% and the counter continues to rise. Closed at 0.0322 and opened at 0.039, the share currently stands at 0.0711. Especially the fact that this share turns out to surpass itself on a weekly basis tastes like more. It’s going exponentially fast and the apex doesn’t seem to be reached yet. The feeling of not wanting to miss the boat seems to be playing up with several investors. Because of the COVID-19, the medical market is showing a lot of interest. The RxAir is a clever response to this by improving the air quality to such an extent that hospitals want to equip themselves with the Vytex and RxAir products.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.
